LONDON :British medical
charity MRC Tech**logy has pocketed
0 million by selling part of its
royalty interest in
Merck & Co´s successful
cancer drug Keytruda, allowing it to plough fresh funds into new research.
The
charity said on Friday that a private equity fund managed by DRI Capital had acquired a portion of its royalty entitlement on the worldwide sales of the medicine.
Keytruda is one of a promising class of new treatments that stimulate the body´s immune system to fight cancer.
It is an antibody-based medicine and was "humanised" by scientists at MRC Tech**logy.
أكثر...